查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018565

合成生物學市場：按產品、技術、應用和最終用戶分類－2026-2032年全球市場預測

Synthetic Biology Market by Product, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，合成生物學市場價值將達到 158 億美元，到 2026 年將成長到 182.5 億美元，到 2032 年將達到 481.8 億美元，年複合成長率為 17.26%。

主要市場統計數據
基準年 2025 158億美元
預計年份：2026年 182.5億美元
預測年份 2032 481.8億美元
複合年成長率 (%) 17.26%

這是一份簡明扼要且具有戰略意義的指南，概述了合成生物學的跨學科創新及其對商業和科學領域領導者的戰略意義。

本執行摘要介紹了合成生物學，指出其本質上是一個跨學科領域，正在重塑生物系統的設計、工程和規模化生產方式，以用於商業用途。本文闡明了合成生物學在計算設計、精密工程和實驗室創新融合的背景下所處的地位，這些融合將催生農業、工業製造、環境應用和生命科學領域的新型產品和服務。透過探討技術能力和市場准入動態，本文重點指出了決策者應優先關注和投資的領域。

自動化、運算設計和先進基因組學的快速整合如何重新定義競爭優勢，並加速各產業的創新產品。

合成生物學正經歷一場變革性的轉變，其意義遠不止於技術進步，而是從根本上改變了產品的構思、設計和交付方式。其中一個最重要的變革是計算設計工具與實驗室自動化技術的日益融合，將「設計、建造、測試、學習」的週期從數月縮短至數週。這種融合使團隊能夠快速迭代基因建構、代謝途徑和合成底盤，從而創造出新的產品類型，同時降低缺乏深厚實驗室經驗的機構進入該領域的門檻。

我們將評估近期關稅變化如何重塑我們的採購、製造和購買策略，以及這些變化如何具體影響我們的韌性和產品交付時間。

美國近期貿易政策的變化和關稅調整，為依賴跨境供應鏈採購設備、耗材和特殊試劑的企業帶來了新的成本考量。關稅的累積影響在整個價值鏈中分佈不均，而定序儀和合成設備等資本設備受進口關稅的影響遠大於模組化軟體或本地服務。這種不平衡獎勵企業重新評估籌資策略，加快特定生產流程的在地化，並在受影響較小的地區尋找替代供應商。

多維細分分析揭示了產品、技術、應用和最終用戶要素如何相互交織，並塑造採用通路和商業化策略。

深入的市場區隔揭示了價值的創造點、功能的集中方式以及通往商業化的路徑。從產品角度來看，市場涵蓋耗材和試劑、儀器、服務和軟體。在耗材和試劑中，酵素和蛋白質、試劑盒和檢測方法以及培養基和補充劑的購買行為和生命週期需求各不相同。另一方面，儀器包括生物資訊工作站、PCR儀、定序儀和合成設備，它們構成了實驗室功能和資本投資規劃的基礎。這種產品觀點闡明了一次性資本投資和持續試劑成本之間的購買週期差異，為策略夥伴關係和定價模型提供了寶貴的資訊。

區域趨勢比較和策略意義，顯示了管理體制、製造能力和資金籌措生態系統如何影響全球市場採用。

區域趨勢對科技的採納、監管和商業化方式有顯著影響。比較美洲、歐洲、中東和非洲以及亞太地區，可以凸顯它們在優先事項和優勢上的差異。在美洲，由強大的創業投資網路和領先的研究機構支持的創新生態系統，往往能夠加速轉化研究和早期商業化進程，尤其在支持治療和診斷的生命科學應用以及合成生物學平台方面具有優勢。此外，該地區的法規環境以及與大規模生物技術叢集的接近性，也有利於研究與市場准入活動之間的快速迭代。

競爭格局分析揭示了平台整合、專家創新和策略夥伴關係為何是決定誰能在合成生物學市場成功擴大業務規模的關鍵因素。

合成生物學領域的競爭格局由那些融合平台技術、深厚的應用領域專業知識和一體化服務交付能力的公司所塑造。主要企業優先考慮在設計工具、設備和服務方面進行垂直整合，以更好地掌控價值鏈，減輕終端用戶的負擔。這些一體化企業通常會大力投資於自身的資料資產和工作流程自動化，從而能夠縮短開發週期，並提供比專注於更狹窄領域的競爭對手更高的可重複性和擴充性。

領導者可採取的策略重點是協調基礎設施、管治、人才和夥伴關係關係，以加速商業化，同時管理法規和供應風險。

行業領導企業應優先考慮一系列切實可行的措施，使技術能力與商業性需求和監管現實相契合。首先，投資模組化基礎設施以支援快速迭代開發。實施互通設備、標準化資料格式以及實現實驗室自動化將縮短開發週期並降低錯誤率。這些投資不僅能加速創新，還能隨著產品系列的擴展帶來營運優勢。其次，透過供應商關係多元化、評估區域生產夥伴關係關係以及協商靈活的合約來降低關稅和物流波動風險，從而增強供應鏈韌性。積極主動的採購計畫將減少停機時間，並保持研發動能。

我們採用透明的混合方法研究途徑，結合訪談、技術文獻和情境分析，為決策者提供可操作的、檢驗的見解。

本概要的研究採用了一種混合方法，旨在補充定性見解和定量檢驗，並強調可重複性和透明度。主要研究包括對儀器製造商、試劑供應商、服務供應商和最終用戶組織的管理人員、研發負責人和採購專家進行結構化訪談。這些訪談提供了有關採用促進因素、採購週期以及近期政策變化帶來的商業性影響的背景資訊。次要研究則納入了同行評審的科學文獻、監管指南和技術白皮書，以闡明技術說明的依據，並準確描述該方法的適用性和局限性。

一項權威的綜合分析強調了將平台功能、穩健的營運結構和合乎道德的管治相結合，從而將科學潛力轉化為持久的商業性價值的必要性。

總之，合成生物學正處於一個轉捩點，技術融合、政策環境演變和經營模式變革既帶來了巨大的機遇，也帶來了顯而易見的風險。採用模組化自動化、建立互通軟體和資料管理方法以及建立彈性供應鏈的組織，將更有能力將科學創新轉化為永續的商業性成果。此外，積極解決管治、倫理問題和外部透明度問題的組織，將減少監管流程中的摩擦，並增強相關人員的信任。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 合成生物學市場：依產品分類

  • 耗材和試劑
    • 酵素和蛋白質
    • 試劑盒檢測
    • 培養基和添加劑
  • 裝置
    • 生物資訊工作站
    • PCR裝置
    • 序列器
    • 合成器
  • 服務
  • 軟體

第9章 合成生物學市場：依技術分類

  • 生物資訊學工具
    • 資料管理
    • 設計自動化
    • 序列分析
  • 細胞工程
    • 細胞株構建
    • 合成細胞設計
  • 基因合成
    • DNA列印
    • 基因組裝
    • 寡核苷酸合成
  • 基因組編輯
    • CRISPR-Cas
    • Meganucleases
  • 合成基因組學
    • 最小細胞
    • 異種生物學

第10章 合成生物學市場：依應用領域分類

  • 農業
    • 基因改造作物
    • 合成肥料
  • 環境
    • 生物修復
    • 碳回收
    • 廢棄物處理
  • 產業
    • 生物催化劑
    • 生質燃料
    • 生質塑膠和生物聚合物
    • 特種化學品
  • 生命科學
    • 藥物發現
    • 基因治療
    • 個人化醫療
    • 疫苗研發

第11章 合成生物學市場：依最終用戶分類

  • 學術和研究機構
  • 農業和食品公司
  • 合約研究機構
  • 製藥和生物技術公司

第12章 合成生物學市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 合成生物學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 合成生物學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國合成生物學市場

第16章 中國合成生物學市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Amyris, Inc.
  • Arzeda
  • Batavia Biosciences BV
  • Beam Therapeutics
  • Beckman Coulter, Inc. by Danaher Corporation
  • BGI Genomics Co., Ltd.
  • Codexis, Inc.
  • Conagen, Inc.
  • Creative Enzymes
  • DNA TwoPointO Inc.
  • Editas Medicine, Inc.
  • Eurofins Scientific SE
  • GenScript Biotech Corporation
  • Ginkgo Bioworks, Inc.
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Merck KGaA
  • New England Biolabs GmbH
  • Novozymes A/S
  • Precigen, Inc.
  • QIAGEN NV
  • Sangamo Therapeutics
  • Scarab Genomics, LLC
  • Synlogic
  • Synthego Corporation
  • TeselaGen Service
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
Product Code: MRR-B9334AD6BE33

The Synthetic Biology Market was valued at USD 15.80 billion in 2025 and is projected to grow to USD 18.25 billion in 2026, with a CAGR of 17.26%, reaching USD 48.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.80 billion
Estimated Year [2026] USD 18.25 billion
Forecast Year [2032] USD 48.18 billion
CAGR (%) 17.26%

A concise and strategic orientation that frames synthetic biology's multidisciplinary innovations and their strategic implications for commercial and scientific leaders

This executive summary introduces synthetic biology as a fundamentally interdisciplinary field that is reshaping how biological systems are designed, engineered, and scaled for commercial use. The introduction situates synthetic biology within a landscape where computational design, precision engineering, and wet-lab innovation converge to enable new classes of products and services across agriculture, industrial manufacturing, environmental applications, and life sciences. By framing the discussion around both technological capability and market adoption dynamics, the narrative emphasizes where decision-makers should prioritize attention and investment.

The section proceeds by articulating the core value propositions that synthetic biology unlocks for organizations: accelerated product development cycles through modular design automation, enhanced reproducibility via standardized biological parts, and downstream cost advantages where engineered biology displaces traditional chemical or agricultural processes. It further highlights how partnerships between software developers, instrument manufacturers, and service providers form the ecosystem that makes advanced biological engineering commercially tractable. The introduction closes by outlining the structure of the analysis to follow, clarifying that subsequent sections will examine transformative shifts, policy impacts, segmentation insights, regional dynamics, competitive positioning, recommendations for leaders, research methods, and conclusive context to support strategic decisions.

How rapid integration of automation, computational design, and advanced genomics is rewriting competitive advantage and accelerating product innovation across sectors

Synthetic biology is experiencing transformative shifts that extend beyond incremental technological improvements to fundamental changes in how products are conceived, designed, and delivered. One of the most consequential shifts is the increasing integration of computational design tools with lab automation, enabling design-build-test-learn cycles to compress from months to weeks. This convergence is unlocking new product classes by allowing teams to iterate rapidly on genetic constructs, metabolic pathways, and synthetic chassis, while also reducing the barriers to entry for organizations without deep wet-lab heritage.

Concurrently, the maturation of modular hardware platforms-ranging from DNA synthesizers and next-generation sequencers to programmable bioreactors-has created standardized interfaces that accelerate interoperability across vendors and labs. As instruments become more accessible and software becomes more sophisticated, a decentralized research model is emerging in which distributed teams can collaborate on shared design repositories and remote execution platforms. This distribution is altering talent dynamics, with demand shifting toward professionals who bridge computational and biological expertise and toward service providers who can deliver end-to-end project execution.

Another axis of transformation is the rise of advanced genome editing and synthetic genomics techniques, which broaden the palette of achievable biological functions. The diffusion of CRISPR-derived tools alongside high-throughput gene synthesis and automated assembly methods is enabling complex engineering tasks such as pathway optimization and chassis minimization at scales that were previously impractical. These technological shifts are paralleled by evolving regulatory conversations and increasing public scrutiny, prompting organizations to adopt more robust governance frameworks and transparent communication strategies. Taken together, these transformations are reshaping competitive advantage to favor entities that can combine platform-scale R&D, cross-disciplinary talent, and disciplined governance into repeatable product development processes.

Assessing how recent tariff shifts have reconfigured sourcing, manufacturing, and procurement strategies with tangible implications for resilience and product delivery timelines

Recent trade policy developments and tariff adjustments in the United States have introduced new cost considerations for companies that rely on cross-border supply chains for instruments, consumables, and specialized reagents. The cumulative impact of tariffs has been felt unevenly across the value chain, with capital equipment such as sequencers and synthesizers bearing higher exposure to import duties relative to modular software and local services. This asymmetry has created incentives for organizations to reassess sourcing strategies, accelerate localization of certain manufacturing processes, and explore alternative suppliers in less affected jurisdictions.

In response, procurement teams and R&D leaders have adopted a mix of short- and medium-term tactics. Short-term responses include renegotiating supply contracts, increasing safety stock of mission-critical consumables, and leveraging contract research organizations to bridge capacity constraints. Over the medium term, companies are contemplating investments in regionalized manufacturing hubs for high-value components and building partnerships that transfer knowledge to local production partners. These shifts are changing the calculus for capital allocation: decision-makers are balancing the need to secure resilient supply chains against the opportunity costs of diverting funds from innovation programs.

At the same time, tariff-driven cost pressures have heightened collaboration between instrument manufacturers and reagent suppliers to create bundled solutions that can be priced and shipped more predictably. Such commercial constructs reduce transactional complexity and help end users manage total cost of ownership. Policy volatility has also elevated the importance of scenario planning and stress-testing of procurement models. Organizations that maintain diversified sourcing, cultivate strategic stockpiles for critical items, and engage proactively with policy advisors will be better positioned to sustain research continuity and mitigate commercial disruption.

Multidimensional segmentation analysis revealing how product, technology, application, and end-user vectors converge to shape adoption pathways and commercialization strategies

Insightful segmentation reveals where value is created, how capabilities cluster, and which pathways lead to commercialization. Based on product, the market spans consumables and reagents, instruments, services, and software; within consumables and reagents, enzymes and proteins, kits and assays, and media and supplements represent distinct purchasing behaviors and lifecycle needs, while instruments encompass bioinformatics workstations, PCR machines, sequencers, and synthesizers that anchor lab capabilities and capital planning. This product lens clarifies how purchasing cycles differ between one-time capital investments and recurring reagent spend, informing strategic partnerships and pricing models.

Based on technology, the landscape is organized around bioinformatics tools, cell engineering, gene synthesis, genome editing, and synthetic genomics; bioinformatics tools further decompose into data management, design automation, and sequence analysis, whereas cell engineering splits into cell line development and synthetic cell design. Gene synthesis breaks down into DNA printing, gene assembly, and oligonucleotide synthesis, while genome editing separates into CRISPR Cas technologies and meganucleases; synthetic genomics includes approaches such as minimal cell design and xenobiology. This technology-based segmentation highlights where R&D investments concentrate and which platform capabilities will be foundational for next-generation products.

Based on application, the field extends across agriculture, environmental, industrial, and life sciences; within agriculture, genetically modified crops and synthetic fertilizers point to agronomic productivity and input optimization, while environmental use cases-bioremediation, carbon capture, and waste treatment-underscore sustainability-focused deployments. Industrial applications include biocatalysts, biofuels, bioplastics and biopolymers, and specialty chemicals, each with distinct scale-up and regulatory paths, and life sciences applications encompass drug discovery, gene therapy, personalized medicine, and vaccine development, where clinical validation and regulatory clearance shape timelines. Finally, based on end user, the market is organized around academic and research institutes, agriculture and food companies, contract research organizations, and pharmaceutical and biotechnology companies, each with unique procurement governance, adoption velocity, and partnership models. Together, these segmentation perspectives form a multidimensional map that leaders can use to align product roadmaps, go-to-market strategies, and partnership priorities with distinct user needs and technology maturities.

Comparative regional dynamics and strategic implications illustrating how regulatory regimes, manufacturing capacity, and funding ecosystems influence adoption across global markets

Regional dynamics materially influence how technologies are adopted, regulated, and commercialized, and a comparative view across the Americas, Europe Middle East and Africa, and Asia-Pacific highlights differentiated priorities and strengths. In the Americas, innovation ecosystems anchored by strong venture capital networks and advanced research institutions tend to accelerate translational activity and early-stage commercialization, with particular strength in life sciences applications and synthetic biology platforms that support therapeutics and diagnostics. This region's regulatory environment and proximity to large biotech clusters also support rapid iterations between research and market-entry activities.

Across Europe, Middle East and Africa, policy frameworks and public funding instruments emphasize biosecurity, ethical governance, and sustainability, which influence the development of environmental and industrial applications. Collaboration between national research centers and industry consortia is common, and regulatory stringency often shapes product design choices, particularly for agricultural and environmental deployments. In the Asia-Pacific region, manufacturing scale, cost-competitive production capacity, and rapidly growing domestic markets create opportunities for scaling upstream production of reagents and instruments as well as for industrial biotech applications such as bioplastics, specialty chemicals, and biofuels. Local regulatory regimes and national industrial strategies in this region can accelerate adoption where alignment exists between government priorities and private-sector investment. Recognizing these regional differentials enables more effective market entry sequencing, supply chain decisions, and talent recruitment strategies that reflect local strengths and constraints.

Competitive landscape insights highlighting why platform integration, specialist innovation, and strategic partnerships determine who scales successfully in synthetic biology markets

Competitive positioning within synthetic biology is shaped by companies that combine platform technologies, deep application expertise, and integrated service offerings. Leading firms prioritize vertical integration across design tools, instruments, and services to capture more of the value chain and to reduce friction for end users. These integrated players often invest heavily in proprietary data assets and workflow automation, enabling them to shorten development cycles and to offer higher levels of reproducibility and scalability than more narrowly focused rivals.

At the same time, specialist companies that focus on a single segment-such as high-precision DNA synthesis, novel enzyme production, or design automation software-retain strategic importance because they drive technical innovation and create partnership opportunities for platform providers. Contract research organizations and service providers play a critical role in de-risking early-stage projects and in enabling companies without large internal labs to access advanced capabilities. Partnerships between instrument manufacturers and reagent suppliers are increasingly common as a means to create turnkey solutions that reduce adoption friction for end users.

Investor attention and strategic partnerships are frequently directed toward firms that demonstrate clear pathways to regulatory readiness, strong intellectual property positions, and defensible data moats. Organizations that can articulate robust safety and governance models alongside compelling technical performance are better positioned to win public trust and to accelerate commercialization. Ultimately, competitive differentiation increasingly depends on the ability to translate technical capability into repeatable commercial processes that customers can deploy reliably at scale.

Actionable strategic priorities for leaders to align infrastructure, governance, talent, and partnerships to accelerate commercialization while managing regulatory and supply risks

Industry leaders should prioritize a set of actionable measures that align technological capability with commercial imperatives and regulatory realities. First, invest in modular infrastructure that supports rapid iteration: adopt interoperable instruments, standardize data formats, and implement laboratory automation to compress development timelines and reduce error rates. These investments not only speed innovation but also create operational leverage as product portfolios expand. Second, develop supply chain resilience by diversifying supplier relationships, evaluating regional production partnerships, and negotiating flexible contracts to mitigate tariff and logistics volatility. Proactive procurement planning reduces downtime and preserves R&D momentum.

Third, adopt robust governance and stakeholder engagement strategies that transparently address biosafety, biosecurity, and ethical considerations. Clear communication and third-party validation of safety frameworks will be essential for building public trust and for smoothing regulatory interactions. Fourth, cultivate cross-disciplinary talent by investing in training programs that bridge computational, molecular, and engineering skill sets; fostering internal centers of excellence will accelerate the integration of design automation and lab execution. Fifth, pursue targeted partnerships and platform bundling with complementary vendors to deliver turnkey solutions for customers, thereby lowering adoption barriers and creating recurring revenue opportunities. Finally, embed scenario planning and stress-testing into strategic processes to prepare for policy shifts, supply disruptions, and rapid technology changes. Leaders who combine operational resilience, ethical governance, and focused commercialization pathways will capture the most enduring advantages.

A transparent, mixed-methods research approach combining interviews, technical literature, and scenario analysis to produce actionable and validated insights for decision-makers

The research underpinning this summary employed a mixed-methods approach designed to triangulate qualitative insight with quantitative validation, emphasizing reproducibility and transparency. Primary research included structured interviews with executives, R&D leaders, and procurement specialists across instrument manufacturers, reagent suppliers, service providers, and end-user organizations. These conversations provided context on adoption drivers, procurement cycles, and the commercial implications of recent policy shifts. Secondary research incorporated peer-reviewed scientific literature, regulatory guidance, and technical white papers to ground technological descriptions and to ensure accuracy in portraying method capabilities and limitations.

Analytical methods combined thematic analysis of interview data with comparative technology mapping to identify capability clusters and adoption pathways. Supply chain and tariff impact assessments were informed by scenario analysis and procurement case studies that illustrate potential operational responses without relying on a single forecast. Throughout, quality controls included cross-validation of claims against multiple independent sources and review cycles with subject-matter experts to ensure factual accuracy and to correct technical nuance. The methodology focused on delivering insight that is both actionable and defensible, enabling leaders to make informed decisions about investment, partnerships, and operational resilience.

A conclusive synthesis underscoring the critical need to combine platform capability, resilient operations, and ethical governance to translate scientific potential into enduring commercial value

In conclusion, synthetic biology stands at an inflection point where technological convergence, evolving policy environments, and shifting commercial models create both significant opportunity and distinct risk. Organizations that adopt modular automation, cultivate interoperable software and data practices, and develop resilient supply chains will be better positioned to translate scientific innovation into sustainable commercial outcomes. Moreover, those that proactively address governance, ethical concerns, and public transparency will reduce friction in regulatory pathways and strengthen stakeholder trust.

The cumulative effect of these dynamics is a marketplace where competitive advantage accrues to entities that can coordinate platform capabilities, talent, and go-to-market execution while remaining adaptable to policy and supply-chain variability. Strategic clarity-rooted in rigorous segmentation, regional awareness, and a commitment to operational excellence-will separate leaders from followers. For any organization engaging with synthetic biology, the imperative is to act deliberately: align internal capabilities with external partnerships, stress-test assumptions under multiple scenarios, and embed ethical governance as a core business practice to sustain long-term value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Synthetic Biology Market, by Product

  • 8.1. Consumables & Reagents
    • 8.1.1. Enzymes & Proteins
    • 8.1.2. Kits & Assays
    • 8.1.3. Media & Supplements
  • 8.2. Instruments
    • 8.2.1. Bioinformatics Workstations
    • 8.2.2. PCR Machines
    • 8.2.3. Sequencers
    • 8.2.4. Synthesizers
  • 8.3. Services
  • 8.4. Software

9. Synthetic Biology Market, by Technology

  • 9.1. Bioinformatics Tools
    • 9.1.1. Data Management
    • 9.1.2. Design Automation
    • 9.1.3. Sequence Analysis
  • 9.2. Cell Engineering
    • 9.2.1. Cell Line Development
    • 9.2.2. Synthetic Cell Design
  • 9.3. Gene Synthesis
    • 9.3.1. DNA Printing
    • 9.3.2. Gene Assembly
    • 9.3.3. Oligonucleotide Synthesis
  • 9.4. Genome Editing
    • 9.4.1. CRISPR Cas
    • 9.4.2. Meganucleases
  • 9.5. Synthetic Genomics
    • 9.5.1. Minimal Cell
    • 9.5.2. Xenobiology

10. Synthetic Biology Market, by Application

  • 10.1. Agriculture
    • 10.1.1. Genetically Modified Crops
    • 10.1.2. Synthetic Fertilizers
  • 10.2. Environmental
    • 10.2.1. Bioremediation
    • 10.2.2. Carbon Capture
    • 10.2.3. Waste Treatment
  • 10.3. Industrial
    • 10.3.1. Biocatalysts
    • 10.3.2. Biofuels
    • 10.3.3. Bioplastics & Biopolymers
    • 10.3.4. Specialty Chemicals
  • 10.4. Life Sciences
    • 10.4.1. Drug Discovery
    • 10.4.2. Gene Therapy
    • 10.4.3. Personalized Medicine
    • 10.4.4. Vaccine Development

11. Synthetic Biology Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Agriculture & Food Companies
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Synthetic Biology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Synthetic Biology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Synthetic Biology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Synthetic Biology Market

16. China Synthetic Biology Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Amyris, Inc.
  • 17.7. Arzeda
  • 17.8. Batavia Biosciences B.V.
  • 17.9. Beam Therapeutics
  • 17.10. Beckman Coulter, Inc. by Danaher Corporation
  • 17.11. BGI Genomics Co., Ltd.
  • 17.12. Codexis, Inc.
  • 17.13. Conagen, Inc.
  • 17.14. Creative Enzymes
  • 17.15. DNA TwoPointO Inc.
  • 17.16. Editas Medicine, Inc.
  • 17.17. Eurofins Scientific SE
  • 17.18. GenScript Biotech Corporation
  • 17.19. Ginkgo Bioworks, Inc.
  • 17.20. Illumina, Inc.
  • 17.21. Integrated DNA Technologies, Inc.
  • 17.22. Merck KGaA
  • 17.23. New England Biolabs GmbH
  • 17.24. Novozymes A/S
  • 17.25. Precigen, Inc.
  • 17.26. QIAGEN N.V.
  • 17.27. Sangamo Therapeutics
  • 17.28. Scarab Genomics, LLC
  • 17.29. Synlogic
  • 17.30. Synthego Corporation
  • 17.31. TeselaGen Service
  • 17.32. Thermo Fisher Scientific Inc.
  • 17.33. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SYNTHETIC BIOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SYNTHETIC BIOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SYNTHETIC BIOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SYNTHETIC BIOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 311. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 312. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 313. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 314. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2018-2032 (USD MILLION)
  • TABLE 316. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 317. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 318. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2018-2032 (USD MILLION)
  • TABLE 319. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 320. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 322. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2018-2032 (USD MILLION)
  • TABLE 323. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 324. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2018-2032 (USD MILLION)
  • TABLE 325. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. EUROPEAN UNION SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 328. EUROPEAN UNION SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 330. EUROPEAN UNION SYNTHETIC BIOLOGY MARKET SIZE, BY TE